Aclarion says first patients enrolled at two additional CLARITY trial sites

Aclarion (ACON) announced that Northwestern Medicine and Scripps Health have enrolled their first patients in the company’s pivotal CLARITY trial, advancing enrollment progress in the trial. The company aims to enroll approximately 25% of patients by the end of Q2 2026. An initial readout on the results of this first cohort of patients will be internally available 90 days later upon the last patient completing their 3-month follow up visit. Additional patient data will be added to the initial readout on a rolling basis until enrollment is completed. Although Aclarion targets full enrollment of 300 patients by mid-2027, if statistically significant improvements are seen in the Nociscan group prior to reaching 300 patients, the trial may be terminated prior to full enrollment. The analysis will evaluate patient-reported pain outcomes using the Visual Analog Scale, the trial’s primary endpoint, with comparisons to pre-surgical pain levels.